Linked Life Data

17285099

Source:http://linkedlifedata.com/resource/pubmed/id/17285099

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-2-7
pubmed:abstractText
While not always clinically significant, patients with schizophrenia may be at risk for drug-drug interactions (DDIs) with second-generation antipsychotics. Second-generation antipsychotics are increasingly being used in a broader population of patients and, therefore, for those with comorbid illnesses, adjunctive treatments, or other diagnoses, the clinical significance of DDIs is increasing. This paper reviews currently available data concerning DDIs that occur between second generation antipsychotics, and other medications or substances, when metabolized by the cytochrome P-450 (CYP) family of enzymes. This review will assess the clinical relevance of these interactions for physicians and patients with schizophrenia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0048-5764
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
77-97
pubmed:dateRevised
2011-8-25
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.
pubmed:affiliation
Maryland Psychiatric Research Center in the University of Maryland School of Medicine at Baltimore, MD 21228, USA. rconley@mprc.umaryland.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't